Refractory Anemia with Excess Blats (RAEB)
Clinical signs
- dysplastic changes are present in at least 10% of cells from two or more lineages
- prognosis: 25% of patients with RAEB-1 and 33% of patients with RAEB-2 develop
AML, median survival time is 18 (RAEB-1) or 10 (RAEB-2) months
Histology
- the number of blasts in bone marrow is between 5 and 19%
- RAEB-1: 5 – 9% myeloblasts
- RAEB-2: 10 – 19% myeloblasts
